2018 Innovative Projects in Radiation Oncology Awards
The ROI is excited to introduce our five new Innovative Projects in Radiation Oncology award winners. Their projects were submitted in response to the ROI’s request for proposals on topics that were identified as important areas of need when 2017 ASTRO Annual Meeting attendees answered the question: “How do we improve our ability to get radiation to the patients who need it?” Financial toxicity, access, awareness and SBRT emerged as critical topics to address for the field of radiation oncology, and the ROI selected the following talented investigators to receive research grants totaling more than $200,000.
Fumiko Chino, MD, mentored by Yvonne Mowery, MD, PhD, and David Brizel, MD, at Duke University, will prospectively quantify and investigate the impact of high treatment costs for head and neck cancer patients receiving radiation therapy. Patient costs are often overlooked and may be associated with increased symptom burden, poor treatment compliance and increased mortality. Dr. Chino’s passion to conduct research in the emerging field of “financial toxicity” stems from personal experience when she and her late husband went into massive debt to pay for his cancer treatment. Her ground-breaking research has been covered by Forbes, National Public Radio (NPR), U.S. News and World Report and JAMA Oncology.
Rachel Conklin, MMS, PA-C, and her team at the department of radiation oncology at Vanderbilt-Ingram Cancer Center will explore using telehealth to increase access to their radiation oncology survivorship program for patients who receive care at a community facility, which is in a rural area approximately 50 miles from their main campus. This study is an important first step in understanding whether telehealth is an effective method to provide follow-up care for the growing number of cancer survivors who were treated with radiation therapy in the U.S. Additional members of the team include: Eric Shinohara, MD, MS, Debra Friedman, MD, Lisa Kachnic, MD, FASTRO, and Tatsuki Koyama, PhD.
Karen Hoffman, MD, and her team at the University of Texas MD Anderson Cancer Center are prospectively surveying prostate cancer patients to study how receiving counseling from a radiation oncologist in a multidisciplinary clinic increases their awareness of radiation therapy as a treatment option with a favorable side effect profile and whether it changes their treatment choice. Because a large portion of men with localized prostate cancer only meet with a urologist, they may not be aware that radiation therapy is a treatment option with less impact on sexual and urinary function than surgery. The long-term goal of this study is to inform patients, providers and policymakers regarding the best practice environment in which to receive counseling about prostate cancer treatment options.
Nima Nabavizadeh, MD, and his team at the Oregon Health and Science University Department of Radiation Medicine will prospectively study if stereotactic body radiation therapy (SBRT) can be safely used to help patients with hepatocellular carcinoma (HCC) and advanced cirrhosis as they await a liver transplant. The primary aim is to evaluate the ability of SBRT to successfully bridge patients to a liver transplant, particularly in patients with advanced cirrhosis at baseline. His team will also assess treatment-related toxicity and quality of life, as well as the histologic effects of SBRT in explanted livers. The multi-disciplinary liver team will consist of: Kristian Enestvedt, MD, Christian Lanciault, MD, PhD, Alice Fung, MD, Khashayar Farsad, MD, PhD, Joseph Ahn, MD, MS, FACG, Yiyi Chen, PhD, and Ramtin Rahmani.
Chad Tang, MD, along with Benjamin Smith, MD, and Grace Smith, MD, PhD, MPH, at the University of Texas MD Anderson Cancer Center will conduct an analysis to understand the barriers to access and costs associated with four treatment options for patients with prostate cancer—surgery, external beam radiation therapy, brachytherapy and active surveillance. Data from the MarketScan and Medicare databases will be used, which will provide a balanced view across private and public health insurance in both young and old prostate cancer patients on a national level. A prospective survey of patients being treated with surgery and brachytherapy will be used to evaluate financial toxicity. The results could be used to help increase access to radiation treatment options for patients with prostate cancer.